Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Serum Institute of India Pvt. Ltd., a biotechnology company that develops and manufactures vaccines for diphtheria, tetanus, pertussis, Hib, BCG, r-hepatitis B, measles, mumps, and rubella disease.
Serum Institute Of India Private Limited, is an unlisted private company incorporated on 22 May, 1984. It is classified as a private limited company and is located in , Maharashtra. It's authorized share capital is INR 55.00 cr and the total paid-up capital is INR 4.82 cr.
Read more
** All rupee values in INR crores. Based on March 2025 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
State | Type | Address |
---|
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Whole-time Director | Adar Cyrus Poonawalla
Shareholder
|
00044815 | 18 years |
Managing Director | Cyrus Soli Poonawalla
Shareholder
|
00044650 | 18 years |
Whole-time Director | Sunil Gairola | 08893242 | 4 years |
Whole-time Director | Umesh Sharadrao Shaligram | 00212458 | 4 years |
Whole-time Director | Satish Ramchandra Mundra | 00416654 | 16 years |
Whole-time Director | Natasha Adar Poonawalla | 01264082 | 9 years |
Whole-time Director | Prasad Suryakant Kulkarni | 08991838 | 4 years |
Director | Behroze Zavareh Poonawalla | 00044877 | 40 years |
Director | Zavareh Soli Poonawalla
Shareholder
|
00044760 | 41 years |
Whole-time Director | Kedar Shashikant Gokhale | 08788551 | 4 years |
Whole-Time Director | Parag Rajendra Deshmukh | 03377341 | 1 years |
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Sales | 7,201.0 | 25,645.0 | 10,190.0 | 9,549.0 | 9,715.0 |
Operating profit | 4,247.0 | 17,445.0 | 5,630.0 | 4,516.0 | 4,242.0 |
Net profit | 3,891.0 | 11,116.0 | 4,187.0 | 4,278.0 | 4,630.0 |
Gross margin | 94.4 | 84.9 | 88.4 | 86.8 | 86.6 |
Operating margin | 59.0 | 68.0 | 55.2 | 47.3 | 43.7 |
Net margin | 46.7 | 41.6 | 39.0 | 38.6 | 42.7 |
Networth | 21,839.0 | 32,933.0 | 36,902.0 | 41,187.0 | 45,741.0 |
Borrowings | 196.0 | 191.0 | 57.0 | 302.0 | 382.0 |
Assets | 26,446.0 | 37,133.0 | 40,049.0 | 44,654.0 | 48,678.0 |
Debt to equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Current ratio | 1.9 | 2.0 | 3.7 | 4.0 | 4.2 |
ROE | 17.8 | 33.8 | 11.3 | 10.4 | 10.1 |
Days payable | 354.0 | 56.0 | 167.0 | 235.0 | 209.0 |
WC days | 188.0 | 51.0 | 233.0 | 314.0 | 278.0 |
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
Reserves | 21,834.2 | 32,928.2 | 36,897.2 | 41,182.2 | 45,736.2 |
Borrowings + | 196.0 | 191.0 | 57.0 | 302.0 | 382.0 |
Long term borrowings | - | - | - | - | - |
Short term borrowings | 196.0 | 191.0 | 57.0 | 302.0 | 382.0 |
Trade payables + | 391.0 | 591.0 | 540.0 | 812.0 | 746.0 |
Days payable | 354.0 | 56.0 | 167.0 | 235.0 | 209.0 |
Other liabilities + | 4,411.0 | 4,009.0 | 3,090.0 | 3,165.0 | 2,555.0 |
Other non-current liabilities | 456.0 | 535.0 | 714.0 | 691.0 | 662.0 |
Other current liabilities | 3,564.0 | 2,883.0 | 1,836.0 | 1,662.0 | 1,147.0 |
Total liabilities | 26,446.0 | 37,133.0 | 40,049.0 | 44,654.0 | 48,678.0 |
Fixed Assets + | 4,730.0 | 4,754.0 | 6,114.0 | 9,029.0 | 10,472.0 |
Tangible assets | 1,991.0 | 2,279.0 | 2,174.0 | 1,967.0 | 2,309.0 |
CWIP | 2,539.0 | 2,348.0 | 3,853.0 | 6,869.0 | 7,339.0 |
Intangible assets | 200.0 | 127.0 | 87.0 | 193.0 | 824.0 |
LT loans and advances | 226.0 | 68.0 | 331.0 | 211.0 | 34.0 |
Other non-current assets | 13,627.0 | 25,054.0 | 24,679.0 | 24,421.0 | 28,502.0 |
Current assets + | 7,863.0 | 7,257.0 | 8,925.0 | 10,993.0 | 9,670.0 |
Inventories | 2,855.0 | 2,618.0 | 3,735.0 | 4,505.0 | 5,309.0 |
Trade receivables | 2,205.0 | 2,725.0 | 3,079.0 | 2,124.0 | 1,570.0 |
Cash and cash equivalents | 1,757.0 | 953.0 | 733.0 | 1,072.0 | 1,740.0 |
ST loans and advances | 58.0 | - | 328.0 | 178.0 | 183.0 |
Other current assets | 988.0 | 961.0 | 1,050.0 | 3,114.0 | 868.0 |
Total assets | 26,446.0 | 37,133.0 | 40,049.0 | 44,654.0 | 48,678.0 |
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Sales + | 7,201.0 | 25,645.0 | 10,190.0 | 9,549.0 | 9,715.0 |
Sales growth % | 32.23 | 256.13 | -60.27 | -6.29 | 1.74 |
Expenses + | 3,427.0 | 9,779.0 | 5,404.0 | 5,658.0 | 6,190.0 |
Cost of goods | 403.0 | 3,878.0 | 1,181.0 | 1,261.0 | 1,302.0 |
Employee cost | 1,350.0 | 1,917.0 | 1,368.0 | 1,458.0 | 1,504.0 |
Other costs | 1,201.0 | 2,405.0 | 2,011.0 | 2,314.0 | 2,667.0 |
Operating profit + | 4,247.0 | 17,445.0 | 5,630.0 | 4,516.0 | 4,242.0 |
Operating margin % | 59.0 | 68.0 | 55.2 | 47.3 | 43.7 |
Other income | 1,134.0 | 1,073.0 | 543.0 | 1,527.0 | 1,139.0 |
Interest | 43.0 | 70.0 | 64.0 | 65.0 | 84.0 |
Depreciation | 430.0 | 1,509.0 | 780.0 | 560.0 | 633.0 |
Exceptional items | - | - | - | - | - |
Profit before tax | 4,908.0 | 16,939.0 | 5,329.0 | 5,418.0 | 4,664.0 |
Tax | 1,017.0 | 5,823.0 | 1,142.0 | 1,140.0 | 34.0 |
Profit - disc. ops | - | - | - | - | - |
Net profit | 3,891.0 | 11,116.0 | 4,187.0 | 4,278.0 | 4,630.0 |
Net margin % | 46.7 | 41.6 | 39.0 | 38.6 | 42.7 |
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Solvency + | |||||
Total Debt/Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Debt/Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Debt/Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Assets/Equity | 1.2 | 1.1 | 1.1 | 1.1 | 1.1 |
Liquidity + | |||||
Current Ratio | 1.9 | 2.0 | 3.7 | 4.0 | 4.2 |
Quick Ratio | 1.2 | 1.3 | 2.1 | 2.3 | 1.9 |
Interest Coverage | 98.8 | 249.2 | 88.0 | 69.5 | 50.5 |
Performance | |||||
Gross Margin | 94.4 | 84.9 | 88.4 | 86.8 | 86.6 |
Operating Margin | 59.0 | 68.0 | 55.2 | 47.3 | 43.7 |
Net Margin | 46.7 | 41.6 | 39.0 | 38.6 | 42.7 |
Return + | |||||
Return on Equity | 17.8 | 33.8 | 11.3 | 10.4 | 10.1 |
Pre-tax ROCE | 45.2 | 190.9 | 38.5 | 22.9 | 20.2 |
Return on Assets | 14.7 | 29.9 | 10.4 | 9.6 | 9.5 |
Pre-tax ROIC | 17.5 | 48.4 | 13.1 | 9.6 | 7.9 |
Efficiency + | |||||
Days Payable | 354.0 | 56.0 | 167.0 | 235.0 | 209.0 |
Days Inventory | 2,586.0 | 246.0 | 1,154.0 | 1,304.0 | 1,488.0 |
Days Receivable | 112.0 | 39.0 | 110.0 | 81.0 | 59.0 |
Fixed Asset Turnover | 1.5 | 5.4 | 1.7 | 1.1 | 0.9 |
Total Asset Turnover | 0.3 | 0.7 | 0.2 | 0.2 | 0.2 |
Working Capital | |||||
Cash Conversion Cycle | 2,344.0 | 229.0 | 1,097.0 | 1,150.0 | 1,338.0 |
Working Capital Days | 188.0 | 51.0 | 233.0 | 314.0 | 278.0 |
As per information available, the company has no registered charges.
Name | State / Country | Incorporation Year | Paidup Capital |
---|---|---|---|
SERUM INTERNATIONAL B.V. | Netherlands | - | - |
Bilthoven Biologicals B.V. | Netherlands | - | - |
SERUM INSTITUTE INC | United States | - | - |
Serum Life Science Europe Gmbh | Germany | - | - |
SEZ BIOTECH SERVICES PRIVATE LIMITED | 2006 | ₹ 1,300.4 Cr | |
POONAWALLA AVIATION PRIVATE LIMITED | Maharashtra | 2005 | ₹ 2,105.2 Cr |
Serum Life Sciences B.V | Netherlands | - | - |
Serum AMR Products B.V. | Netherlands | - | - |
SERUM INSTITUTE LIFE SCIENCES PRIVATE LIMITED | Maharashtra | 2020 | ₹ 636.6 Cr |
Serum Life Sciences Ltd | United Kingdom | - | - |
COVIDSHIELD TECHNOLOGIES PRIVATE LIMITED | Maharashtra | 2019 | ₹ 7.5 Cr |
SERUM INSTITUTE VACCINES PRIVATE LIMITED | Maharashtra | 2021 | ₹ 113.3 Cr |
SERUM LIFECARE FOUNDATION | Maharashtra | 2023 | ₹ 0.0 |
Serum Global FZCO | United Arab Emirates | - | - |
Serum Middle East Holdings FZCO | United Arab Emirates | - | - |
Diamond Worldwide Finance Ltd | Virgin Islands, British | - | - |
Read more
The incorporation date of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is 22 May, 1984
The authorized share capital of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is INR ₹ 55.0 Cr.
The paid-up capital of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is INR ₹ 4.8 Cr.
The registered address of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is 212/2 OFF SOLI POONAWALLA ROAD, HADAPSAR, Pune, PUNE, Maharashtra, India, 411028 - 411028
The CIN number of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is U80903PN1984PTC032945.